Cutaneous manifestations in a series of 417 patients with SARS-CoV-2 infection: epidemiological and clinical correlates of chilblain like lesions.

A variety of dermatological lesions have been described in COVID-19, although the prevalence and pathogenic relationship remain unclear particularly for chilblain-like lesions. Dermatological examination was performed in a prospective cohort of consecutive patients seen at the service for SARS-CoV-2 infection. Out of 417 patients with confirmed SARS-CoV-2 infection [median age 29.5 years (range 15-65); 62.5% males], dermatological lesions were detected in 7 (1.7%). Three patients had acral lesions; their age (range) was 15-29 years; all had a negative nasopharyngeal swab and developed IgG and/or IgM-specific antibodies; all presented none or mild symptoms. A fourth patient remained negative at repeated testing; mother, father and sister had a documented mild COVID-19. Non-acral lesions were observed in four older patients, with severe COVID-19. Chilblain-like lesions may be the sole manifestation of SARS-CoV-2 infection; their presence in asymptomatic school children and adolescents should be considered a potential signal of familial or community spread of the virus.

Interferon treatment in children with chronic hepatitis C: long-lasting remission in responders, and risk for disease progression in non-responders.

BACKGROUND AND AIM: Large interferon-based therapeutic trials are still lacking in children with hepatitis C and the long-term safety and efficacy of interferon is unknown. This study describes the outcome of hepatitis C in 43 children enrolled in an open-label interferon trial, and were followed up to 66 months after stopping treatment. PATIENTS AND METHODS: All patients received interferon alfa2a (5MU/m(2)) thrice weekly for 6 months; children with genotype 1b received 3MU/m(2) thrice weekly for 6 additional months. RESULTS: Nine children discontinued interferon for adverse events and three were not compliant to treatment. Eight (19%, intention to treat analysis), including 2/20 (10%) with genotype 1b and 6/12 (50%) with genotypes 2 or 3, were sustained responders 12 months after stopping therapy. During further follow-up (mean+/-S.D.: 44.7+/-14.6 months), response was maintained; two non-responders cleared viremia, while a young boy progressed to cirrhosis. CONCLUSIONS: Small sample size and therapy withdrawal are the major limitations in the interpretation of our results. Nevertheless, our data, suggesting that response to interferon in children with hepatitis C is genotype-related and stable, agree with the results of large studies in adults. The outcome in non-responders was variable, including persistence of viremia and mild-moderate cytolysis (most cases), progression to cirrhosis, or eventual sustained viremia clearance.

Absence of maternal antibodies to hepatitis B core antigen and HBV vertical transmission: one case of infection notwithstanding passive-active prophylaxis.

We report the case of a newborn of an HBsAg carrier mother who was infected by vertical transmission and developed a subclinical hepatitis B at four months of age, notwithstanding the passive-active prophylaxis performed right after birth. The mother's HBV marker status was: HBsAg positive, HBeAg positive, anti-HBc IgM positive at low titer, anti-HBc IgG negative, anti-HBs negative, anti-HBe negative. It is assumed that the absence of anti-HBC antibodies might have favoured, perhaps in utero, the HBV infection whose antigenic expression was subsequently delayed by HBIg administered at birth. These findings suggest that the positivity for anti-HBc IgM must be considered an additional marker of maternal infectivity especially in the absence of anti-HBc IgG antibodies.

HBIG efficacy in preventing HBV infection in infants.

Previous studies have confirmed the superiority of HBIG versus ISG and multiple dose versus single dose of HBIG (Beasley) and the time of first HBIG administration in preventing HBV infection. In all studies many treated infants became HBsAg or anti-HBs positive after the HBIG stopped. The present study was undertaken to evaluate the efficacy of multiple dose HBIG therapy in preventing HBV infection, and to establish the optimal dose, the frequency of the dose, the time of administration during the first year of life and to control the occurrence of HBsAg or active anti-HBs during the first two years of life. Seven infants of mothers positive for HBsAg and HBeAg, or positive for HBsAg but negative for HBeAg and anti-HBe, or with hepatitis B in the last trimester of pregnancy, received HBIG at high titer at dose of 0.5 ml/kg from first day until near 5 months of life and then 0.5-0.3 ml/kg until 12 months of life. The interval between the administration was established on the basis of the anti-HBs titer lower than 32. It was not a fixed interval but variable in different cases. Passive anti-HBs antibodies were almost always above 32 during the treatment period with HBIG. All patients remained negative for HBV markers and for liver enzyme tests during the period of the study. HBIG, administered in the first year of life at high dose and at intervals depending upon serum anti-HBs titer (32) systematically controlled, is efficient in preventing the hepatitis B infection in infants at high risk.(ABSTRACT TRUNCATED AT 250 WORDS)

Vertical transmission of HBV from mothers HBsAg positive, anti-HBe positive.

Vertical transmission of HBV from HBsAg carrier mothers to their infants occurs frequently and very early in life. The HBsAg titer, the presence of HBeAg and acute HBV infection in the mother are usually considered facilitating factors; on the contrary anti-HBs and anti-HBe titer would be effectively protecting. However anti-HBc does not prevent HBsAg infection at all. In order to obtain information on the rate of HBV transmission in conditions considered at lower risk, we identified a group of pregnant women who were asymptomatic chronic HBsAg carriers and followed their children for several months after birth with clinical and laboratory examinations. All the 13 mothers were positive for HBsAg, anti-HBe, anti-HBc and negative for anti-HBs and HBeAg. All infants were controlled monthly in the first year of life and then at 16, 20, 24 months. The relatives controlled in the same period proved negative for HBV markers. All infants were negative for antigens at the birth and positive for anti-HBe and anti-HBc. These antibodies disappeared after 3-7 months after birth, indicating maternal transmission. All infants remained negative for HBsAg, HBeAg, anti-HBe and liver enzyme tests during the period of observation (24 months). These observations indicate that in our population the transmission of HBsAg from chronic carrier mothers to their children is not a frequent occurrence; probably the presence of anti-HBe has been protective.(ABSTRACT TRUNCATED AT 250 WORDS)

Transmission of hepatitis C virus from infected mother to offspring during subsequent pregnancies.

BACKGROUND: Several studies have demonstrated that hepatitis C virus (HCV) may be transmitted from mother to offspring. To date, however, little is known about the risk of vertical transmission during subsequent pregnancies. The purpose of this study was to evaluate the risk of vertical HCV transmission in offspring in subsequent pregnancies of HCV infected women. METHODS: In a multicenter study, two groups of index cases were selected. Group 1 included 75 children investigated for HCV infection during prospective studies of vertical transmission. Group 2 included children born to HCV-infected mothers and found to be HCV infected, independent of studies on vertical transmission. All children in the index cases had one or more siblings. Anti-HCV, HCV-RNA (determined by polymerase chain reaction), and HCV genotype were evaluated in all the infected children, their mothers, and siblings. RESULTS: The results indicate that a mother who has already delivered an HCV-infected baby is not at greater risk of infecting her second child. Duration of maternal infection does not seem to be a risk factor in offspring infection, because HCV infection is equally distributed among first-born infants and infants of subsequent births. Because clustering of HCV infection among siblings appeared to be rare in this study, data also indirectly confirm that the risk of horizontal transmission of HCV among siblings is low. CONCLUSION: For practical purposes, the current observations indicate that mothers who have already delivered an HCV-infected child can be advised that this event does not increase the probability of infecting the second child.

Changing epidemiologic pattern of chronic hepatitis C virus infection in Italian children.

OBJECTIVE: To evaluate the epidemiologic features of chronic hepatitis C virus (HCV) infection in children. STUDY DESIGN: All 106 children with chronic HCV infection consecutively observed in 3 Italian pediatric centers between 1991 and 1997 entered the study. RESULTS: Fifteen children had a history of non-A, non-B hepatitis, and 5 complained of nonspecific symptoms. The 86 remaining patients were free of symptoms and were recruited after HCV screening for intercurrent diseases, maternal infection, or other putative exposure; 39% (none of 30 children born after 1990) had received transfusions, whereas 44%, had a mother with HCV infection. Of the 47 infected mothers, 36% were or had been intravenous drug users, 15% had received transfusions, and 45% had no history of exposure. CONCLUSIONS: Children with chronic HCV infection are often free of symptoms, and thus HCV screening for putative risk has greatly increased the chances of diagnosis. Vertical transmission seems to now be the most common route of infection. Both current and past maternal intravenous drug abuse are risk factors for pediatric infection; however, in an area with relatively high prevalence of anti-HCV in the general population such as Italy, a consistent proportion of infectious mothers have no risk factors of HCV exposure.

Hepatitis C virus infection and related liver disease in children of mothers with antibodies to the virus.

OBJECTIVE: To evaluate the clinical, biochemical, and virologic features associated with hepatitis C virus (HCV) infection acquired early in life from mothers with antibodies to HCV (anti-HCV). STUDY DESIGN: Multicenter prospective-retrospective study in Italian children. PATIENTS: Two groups of children were investigated. Group 1 included 14 infants, born to mothers with anti-HCV but without human immunodeficiency virus infection, who became seropositive for HCV RNA during the first year of life and were thus considered infected. Group 2 included 16 children with chronic hepatitis C, aged 1 1/2 to 14 years, whose mothers were the unique potential source of infection. Both groups were followed for 12 to 48 months. METHODS: Alanine transaminase (ALT), anti-HCV, and HCV RNA were investigated by the polymerase chain reaction on entry to the study and during follow-up. RESULTS: All children in group 1 had anti-HCV throughout follow-up, and all had ALT abnormalities, ranging from 1.5 to 10.5 times the normal value during the first 12 months. During further follow-up, 5 of 10 children had HCV RNA with abnormal ALT values, 3 had a return to normal of the ALT values but continued to have viremia, and 2 eventually had normal ALT values and clearance of HCV RNA. Of the 16 children in group 2, all were free of symptoms and 62% had only slight ALT elevations; 7 who underwent liver biopsy had histologic features of minimal or moderate hepatitis. CONCLUSIONS: HCV infection acquired early in life from mothers with anti-HCV is usually associated with biochemical features of liver damage during the first 12 months of life. Progression to chronicity seems to occur in the majority of cases, although HCV-associated liver disease is likely to be mild throughout infancy and childhood.